Related Experiment Video

Updated: May 24, 2025

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

11.5K

PHD-2/HIF-1α axis mediates doxorubicin-induced angiogenesis in SH-SY5Y neuroblastoma microenvironment: a potential

Ahmed M Abou-Shanab1,2, Ola A Gaser1,2, Noha Galal2

  • 1Center of Excellence for Stem Cells and Regenerative Medicine, Zewail City of Science and Technology, Giza, 12578, Egypt.

Scientific Reports
|March 3, 2025
PubMed

Insights

Doxorubicin, a neuroblastoma treatment, unexpectedly promotes blood vessel growth by upregulating pro-angiogenic factors and activating pathways like Pi3K, suggesting new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Neuroblastoma (NB) treatment response and microenvironment influence are not fully understood.
  • Doxorubicin is a common chemotherapeutic agent for NB.

Purpose of the Study:

  • To investigate the molecular mechanisms by which doxorubicin affects the SH-SY5Y NB cell microenvironment.
  • To determine if doxorubicin induces pro-angiogenic responses in NB cells.

Main Methods:

  • SH-SY5Y cells were treated with doxorubicin.
  • Co-culture systems with human umbilical vein endothelial cells (HUVECs) were used.
  • In-ovo studies, molecular docking, simulations, and bioinformatics analyses were performed.

Main Results:

  • Doxorubicin reduced SH-SY5Y cell proliferation but increased pro-angiogenic factors (VEGF, PDGF, MMP-2) and nitric oxide.
  • HUVECs showed enhanced proliferation, migration, tube formation, and nitric oxide production.
  • In-ovo studies confirmed doxorubicin-induced neo-angiogenesis; HIF-1α stabilization and Pi3K pathway activation were observed.

Conclusions:

  • Doxorubicin unexpectedly induces a pro-angiogenic response in the NB microenvironment.
  • Targeting PHD-2 and utilizing multi-modal therapies may offer improved NB treatment outcomes.
Keywords:
DoxorubicinNeo-angiogenesisNeuroblastoma angiogenesisPHD-2/HIF-1α targetingTumor microenvironment

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.9K
Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

12.3K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K